WO2025149070 - SYNTHESIS AND USE OF NOVEL PROTEOLYSIS CHIMERA COMPOUND TARGETING INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 (IRAK4)
National phase entry is expected:
Publication Number
WO/2025/149070
Publication Date
17.07.2025
International Application No.
PCT/CN2025/071930
International Filing Date
10.01.2025
Title **
[English]
SYNTHESIS AND USE OF NOVEL PROTEOLYSIS CHIMERA COMPOUND TARGETING INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 (IRAK4)
[French]
SYNTHÈSE ET UTILISATION D'UN NOUVEAU COMPOSÉ CHIMÈRE DE PROTÉOLYSE CIBLANT LA KINASE 4 ASSOCIÉE AU RÉCEPTEUR DE L'INTERLEUKINE-1 (IRAK4)
[Chinese]
一种新型靶向白细胞介素1受体关联激酶4(IRAK4)的蛋白降解嵌合体化合物的合成及其应用
Applicants **
GAN & LEE PHARMACEUTICALS CO., LTD.
Inventors
CHEN, Wenmin
XU, Fuming
SHAO, Wenjie
CHEN, Jingjing
ZHANG, Yuna
LI, Lu
WANG, Kanghua
YU, Weiwei
Priority Data
202410036991.2
10.01.2024
CN
202410660238.0
27.05.2024
CN
202410925767.9
11.07.2024
CN
202410973486.0
19.07.2024
CN
202411165877.6
23.08.2024
CN
202411510785.7
28.10.2024
CN
202411611270.6
12.11.2024
CN
202411789874.X
06.12.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 8313 | |
| EPO | Filing, Examination, Granting | 32619 | |
| Japan | Filing, Examination, Granting | 2482 | |
| South Korea | Filing, Examination, Granting | 3005 | |
| USA | Filing, Examination, Granting | 9340 |
Total:
55,759
Contact Us
Abstract[English]
The present invention relates to the technical field of chemical pharmacy, and in particular to a compound for degradation of a targeted interleukin-1 receptor-associated kinase 4 (IRAK4), and a pharmaceutically acceptable salt of the compound. The compound can be used for treating or preventing IRAK4-mediated immune diseases, inflammatory diseases, and cancers.[French]
La présente invention concerne le domaine technique de la chimiopharmaceutique, et en particulier un composé pour la dégradation d'une kinase 4 associée au récepteur de l'interleukine-1 ciblée (IRAK4), et un sel pharmaceutiquement acceptable du composé. Le composé peut être utilisé pour traiter ou prévenir des maladies immunitaires à médiation par IRAK4, des maladies inflammatoires et des cancers.[Chinese]
本发明涉及化学制药技术领域，具体涉及一种用作靶向白细胞介素1受体关联激酶4(IRAK4)降解的化合物及其药学上可接受的盐，其可用于作为治疗或预防由IRAK4介导的免疫性疾病、炎症疾病和癌症。